AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19746764 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid (AzA) gel 15% applied twice daily
Number of subjects: 102
Study 19746764 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial cleanser used before AzA application
Number of subjects: 102
Study 19746764 — intervention group
Group type: COMPARATOR
Intervention: No moisturizer applied to the left side of the face
Number of subjects: 102
Study 17210892 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal diffusion-weighted imaging
Number of subjects: 22
Study 15491065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 or 20 mg/day)
Number of subjects: 42
Study 15491065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10762562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 1178
Study 10762562 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin
Number of subjects: 1178
Study 10762562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Clarithromycin + Rifabutin)
Number of subjects: 1178
Study 10762562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Combination therapy
Number of subjects: 1178
Study 10762562 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 1178
Study 8732472 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50
Number of subjects: 419
Study 8732472 — intervention group
Group type: COMPARATOR
Intervention: Premarin 0.625 mg/day
Number of subjects: 419
Study 8732472 — intervention group
Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 419
Study 1348475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP)
Number of subjects: 10
Study 1348475 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 10
Study 3901675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 73
Study 3901675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30887671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing at 48 hours after birth
Number of subjects: 73
Study 30887671 — intervention group
Group type: COMPARATOR
Intervention: Bathing at 24 hours after birth
Number of subjects: 73
Study 29164798 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in CSF Aβ levels and evident tau pathology
Number of subjects: 88
Study 29164798 — intervention group
Group type: COMPARATOR
Intervention: Normal levels of tau
Number of subjects: 88
Study 27197662 — intervention group
Group type: EXPERIMENTAL
Intervention: FEX 60 mg with 150 mL of AJ
Number of subjects: 10
Study 27197662 — intervention group
Group type: EXPERIMENTAL
Intervention: FEX 60 mg with 300 mL of AJ
Number of subjects: 10
Study 27197662 — intervention group
Group type: EXPERIMENTAL
Intervention: FEX 60 mg with 600 mL of AJ
Number of subjects: 10
Study 27197662 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 25511058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine derived hydroxyapatite (BHA)
Number of subjects: 24
Study 25511058 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic hydroxyapatite (SHA)
Number of subjects: 24
Study 23359361 — intervention group
Group type: EXPERIMENTAL
Intervention: D-xylose preload with sitagliptin (SX)
Number of subjects: 12
Study 23359361 — intervention group
Group type: EXPERIMENTAL
Intervention: D-xylose preload without sitagliptin (PX)
Number of subjects: 12
Study 23359361 — intervention group
Group type: COMPARATOR
Intervention: Sucralose control (C)
Number of subjects: 12
Study 23359361 — intervention group
Group type: EXPERIMENTAL
Intervention: D-xylose preload (X)
Number of subjects: 12
Study 20802289 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnitude (HM; 50 Hz and 2.51 mmp‐p; 98.55 mxs‐2)
Number of subjects: 20
Study 20802289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnitude (LM; 30 Hz and 1.15 mmp‐p; 20.44 m.s‐2)
Number of subjects: 20
Study 20802289 — intervention group
Group type: COMPARATOR
Intervention: Control (without vibration stimulus)
Number of subjects: 20
Study 18206190 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated L-phenylalanine (Phe)
Number of subjects: 20
Study 18206190 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 20
Study 18206190 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated L-phenylalanine (Phe) in the follicular phase for women in the lower 50th percentile of rigid restraint
Number of subjects: 20
Study 18206190 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated L-phenylalanine (Phe) in the luteal phase for women in the higher 50th percentile of rigid restraint
Number of subjects: 20
Study 16427245 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 340
Study 16427245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 340
Study 16427245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 340
Study 12815350 — intervention group
Group type: EXPERIMENTAL
Intervention: C&B Metabond (adhesive resin cement)
Number of subjects: 120
Study 12815350 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia (adhesive resin cement)
Number of subjects: 120
Study 12815350 — intervention group
Group type: COMPARATOR
Intervention: Fleck's (zinc phosphate cement)
Number of subjects: 120
Study 12815350 — intervention group
Group type: COMPARATOR
Intervention: Ketac-Cem (conventional glass ionomer cement)
Number of subjects: 120
Study 12815350 — intervention group
Group type: COMPARATOR
Intervention: 6-degree taper
Number of subjects: 120
Study 12815350 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-degree taper
Number of subjects: 120
Study 11078787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 0
Study 11078787 — intervention group
Group type: COMPARATOR
Intervention: Standardized Mini-Mental State Examination
Number of subjects: 0
Study 8866639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of moxisylyte at 10 mg
Number of subjects: 18
Study 8866639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of moxisylyte at 20 mg
Number of subjects: 18
Study 8866639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of moxisylyte at 30 mg
Number of subjects: 18
Study 1630668 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline (400 mg b.i.d.)
Number of subjects: 14
Study 1630668 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (480 mg b.i.d.)
Number of subjects: 14
Study 30049724 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (<30 mm Hg)
Number of subjects: 60
Study 30049724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate (<gestational age mm Hg)
Number of subjects: 60
Study 30049724 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive (<19 mm Hg)
Number of subjects: 60
Study 30049724 — intervention group
Group type: COMPARATOR
Intervention: All groups (after threshold breached)
Number of subjects: 60
Study 30049724 — intervention group
Group type: COMPARATOR
Intervention: Cranial ultrasound findings
Number of subjects: 60
Study 28233684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clensia 2L
Number of subjects: 422
Study 28233684 — intervention group
Group type: COMPARATOR
Intervention: PEG 4L
Number of subjects: 422
Study 24929659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) design
Number of subjects: 99
Study 24929659 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) design
Number of subjects: 99
Study 23943731 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway integrated Nasopore
Number of subjects: 80
Study 23943731 — intervention group
Group type: COMPARATOR
Intervention: Nasopore without airway integration
Number of subjects: 80
Study 21682545 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-visual mode
Number of subjects: 20
Study 21682545 — intervention group
Group type: COMPARATOR
Intervention: Auditory-only mode
Number of subjects: 20
Study 20523282 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thrombolysis
Number of subjects: 3
Study 20523282 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 3
Study 20523282 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 3
Study 16957645 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (fluoroscopic navigation technique)
Number of subjects: 20
Study 16957645 — intervention group
Group type: COMPARATOR
Intervention: Conventional operative technique (fluoroscopy)
Number of subjects: 20
Study 15737519 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 0
Study 15737519 — intervention group
Group type: COMPARATOR
Intervention: Telithromycin 800 mg for 5 days
Number of subjects: 0
Study 12218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) perfusion imaging
Number of subjects: 20
Study 12218421 — intervention group
Group type: EXPERIMENTAL
Intervention: H2(15)O Positron Emission Tomography (PET)
Number of subjects: 20
Study 12218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) and H2(15)O PET agreement in white matter
Number of subjects: 20
Study 12218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) and H2(15)O PET agreement in gray matter
Number of subjects: 20
Study 9469269 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 1 g oral slurry in a single dose
Number of subjects: 106
Study 9469269 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin, 500 mg every 6 hours for 7 days
Number of subjects: 106
Study 7874894 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 40
Study 7874894 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 40
Study 2243372 — intervention group
Group type: EXPERIMENTAL
Intervention: Glypressin
Number of subjects: 29
Study 2243372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitressin
Number of subjects: 29
Study 350388 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 76
Study 350388 — intervention group
Group type: COMPARATOR
Intervention: methanol extracted residue of bacillus Calmette‐Guérin (MER)
Number of subjects: 76
Study 350388 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 76
Study 350388 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (adriamycin, cyclophosphamide, cis‐dichlorodiammineplatinum(II), vincristine)
Number of subjects: 76
Study 30931835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive conventional phototherapy (Bilisphere 360)
Number of subjects: 54
Study 30931835 — intervention group
Group type: COMPARATOR
Intervention: Intensive LED phototherapy (Bilitron bed 3600)
Number of subjects: 54
Study 31005336 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 (10, 25, or 50 mg)
Number of subjects: 49
Study 31005336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29091568 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor
Number of subjects: 443
Study 29091568 — intervention group
Group type: COMPARATOR
Intervention: Statin
Number of subjects: 443
Study 29091568 — intervention group
Group type: COMPARATOR
Intervention: Combination of ACE inhibitor and statin
Number of subjects: 443
Study 26521581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment within first 72 hours after surgery, with needles retained for 30 minutes, given 6 times.
Number of subjects: 80
Study 26521581 — intervention group
Group type: COMPARATOR
Intervention: Postoperative routine care of hand surgery (Control group).
Number of subjects: 80
Study 23806287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen at 4 L/min intranasally
Number of subjects: 20
Study 23806287 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory air at 4 L/min intranasally
Number of subjects: 20
Study 21558575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation
Number of subjects: 9
Study 21558575 — intervention group
Group type: COMPARATOR
Intervention: Skim-milk powder (control)
Number of subjects: 9
Study 21558575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (colostrum and skim-milk powder)
Number of subjects: 9
Study 19423529 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day for 6 months
Number of subjects: 143
Study 19423529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 143
Study 16750790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 64
Study 16750790 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 15087584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 100
Study 15087584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11763936 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevident 5000 Plus (5000 ppm F)
Number of subjects: 201
Study 11763936 — intervention group
Group type: COMPARATOR
Intervention: Colgate Winterfresh Gel (1100 ppm F)
Number of subjects: 201
Study 9368260 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma knowledge beliefs and management behavior; Caretakers demonstrated considerable asthma knowledge, averaging 84% correct responses on the Asthma Information Quiz.
Number of subjects: 1528
Study 9368260 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Behavior Checklist scores; children rated their responsibility for self-care significantly higher than adults.
Number of subjects: 1528
Study 9368260 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Symptom Inventory scores; adults reported elevated levels of psychological distress.
Number of subjects: 1528
Study 9368260 — intervention group
Group type: EXPERIMENTAL
Intervention: Life stress events; caretakers experienced undesirable life events.
Number of subjects: 1528
Study 8111819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg BID
Number of subjects: 250
Study 8111819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg QID
Number of subjects: 250
Study 8111819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 3797019 — intervention group
Group type: EXPERIMENTAL
Intervention: Quota setting alone
Number of subjects: 64
Study 3797019 — intervention group
Group type: EXPERIMENTAL
Intervention: Quota setting with monetary reinforcement
Number of subjects: 64
Study 3797019 — intervention group
Group type: COMPARATOR
Intervention: Quota setting with placebo
Number of subjects: 64
Study 3797019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy expectancies
Number of subjects: 64
Study 3797019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy expectancies and pain tolerance times at treatment
Number of subjects: 64
Study 31452081 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of natalizumab (MDI 6.2 weeks)
Number of subjects: 360
Study 31452081 — intervention group
Group type: COMPARATOR
Intervention: Standard interval dosing (SID) of natalizumab (MDI 4.3 weeks)
Number of subjects: 360
Study 30514285 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised online lifestyle coaching application
Number of subjects: 0
Study 30514285 — intervention group
Group type: COMPARATOR
Intervention: Standard periconceptional advice including information from NHS websites
Number of subjects: 0
Study 27449661 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive RRT (hemodialysis or sustained low‐efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 ml/kg per hour)
Number of subjects: 1124
Study 27449661 — intervention group
Group type: COMPARATOR
Intervention: Less intensive RRT (hemodialysis or sustained low‐efficiency dialysis three times per week or continuous venovenous hemodiafiltration at 20 ml/kg per hour)
Number of subjects: 1124
Study 27449661 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive RRT
Number of subjects: 1124
Study 24808487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplement meal
Number of subjects: 39
Study 24808487 — intervention group
Group type: COMPARATOR
Intervention: Tomato puree meal
Number of subjects: 39
Study 24808487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 39
Study 24808487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 29 SNPs in 15 genes
Number of subjects: 39
Study 22808712 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) - 8-week program, three sessions/week, three sets of 10-12 repetition maximum, five different exercises
Number of subjects: 17
Study 22808712 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 17
Study 20044684 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 103
Study 20044684 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 103
Study 18480921 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related educational programmes for long-term management of atopic dermatitis
Number of subjects: 823
Study 15790459 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m² IV infusion on day 1, Carboplatin AUC 6.0 IV on day 1, Etoposide 50 mg alternating with 100 mg orally on days 1-10, 6 courses at 21-day intervals
Number of subjects: 52
Study 12025735 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory CNV paradigm with paired electrical stimuli as warning stimulus (WS) and imperative stimulus (IS)
Number of subjects: 20
Study 12025735 — intervention group
Group type: COMPARATOR
Intervention: Conventional CNV paradigm with a click sound as WS and a red light flash as IS
Number of subjects: 20
Study 10498115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation at a dosage of 400 IU per day
Number of subjects: 0
Study 10498115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at a dosage of 500 to 1,000 mg per day
Number of subjects: 0
Study 10498115 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0
Study 10498115 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study 7585298 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid supplement containing fat (30 to 36 g) and cholesterol (650 to 780 mg)
Number of subjects: 49
Study 7585298 — intervention group
Group type: COMPARATOR
Intervention: Liquid supplement that was fat and cholesterol free
Number of subjects: 49
Study 2293357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (100 mg orally q.i.d. for 2 days preoperatively, 5 mg/kg body weight/24 h i.v. peroperatively and 100 mg orally q.i.d. for 1 year postoperatively)
Number of subjects: 360
Study 2293357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 2293357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 360
Study 6263091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (300 mg three times daily for 18 days of every 21 day chemotherapy cycle)
Number of subjects: 45
Study 6263091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lithium)
Number of subjects: 45
Study 31927548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serum cystatin C (sCysC) and urinary N-Acetyl-Beta-D-glucosaminidase (uNAG)
Number of subjects: 605
Study 31927548 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of sCysC and uNAG added to predictive model
Number of subjects: 605
Study 31927548 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of sCysC and uNAG
Number of subjects: 605
Study 31927548 — intervention group
Group type: COMPARATOR
Intervention: sCysC, uNAG, and uACR individually
Number of subjects: 605
Study 31927548 — intervention group
Group type: COMPARATOR
Intervention: uNAG plus uACR or sCysC plus uACR
Number of subjects: 605
Study 28597708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training on cycle ergometer (AT-group)
Number of subjects: 48
Study 28597708 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of the lower extremities (RT-group)
Number of subjects: 48
Study 28597708 — intervention group
Group type: COMPARATOR
Intervention: Sham training of upper extremities (ST-group)
Number of subjects: 48
Study 28597708 — intervention group
Group type: COMPARATOR
Intervention: All groups (AT-group, RT-group, ST-group)
Number of subjects: 48
Study 27855643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic anticoagulation (PA group)
Number of subjects: 300
Study 27855643 — intervention group
Group type: COMPARATOR
Intervention: Traditional anticoagulation (TA group)
Number of subjects: 300
Study 27855643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic analysis
Number of subjects: 300
Study 24917273 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg weekly)
Number of subjects: 80
Study 24917273 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (1 g twice daily)
Number of subjects: 80
Study 24917273 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 80
Study 24917273 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 80
Study 22555266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in NYHA functional class I/II
Number of subjects: 667
Study 22555266 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in NYHA functional class III/IV
Number of subjects: 667
Study 20632264 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 70
Study 20632264 — intervention group
Group type: COMPARATOR
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 70
Study 20632264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SILC and MLC
Number of subjects: 70
Study 18846541 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (400 mg/day)
Number of subjects: 704
Study 18846541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 15830236 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 22